GSK supports BMJ commitment on clinical trial data transparency
Posted: 31 October 2012 | | No comments yet
“GSK fully supports the commitment made by BMJ to drive greater transparency of clinical trial data…”
GlaxoSmithKline plc (GSK) today responded to the news that the BMJ will, from January 2013, only publish scientific papers where there is a commitment to make the relevant anonymised patient level data available on reasonable request. This commitment will apply to all clinical trials of drugs and devices, whether industry funded or not.
Patrick Vallance, President, Pharmaceuticals R&D, GlaxoSmithKline, said:
“GSK fully supports the commitment made today by BMJ to drive greater transparency of clinical trial data. Moves like this should help medical research by allowing scientists to study the detailed results of clinical trials and increase understanding of current and new medicines. Ultimately this should improve patient care.
“At GSK we already post results from all our clinical trials – whether positive or negative – on our website. We also aim to publish these in peer reviewed journals such as BMJ. Earlier this month we announced plans to further increase openness and transparency by enabling researchers to access the detailed data that sit behind the results of our clinical trials.
“GSK’s ultimate goal is to see a broad system develop where the clinical research community can access data from trials conducted by different organisations. We want to work with others to make this happen.”
Read more about GSK’s commitment to clinical trial data transparency at gsk.com.
